While CML and BCR::ABL1-negative MPN have been considered to be mutually exclusive [5], the WHO classification requires the exclusion of the BCR::ABL1 fusion in all cases of suspected MPN that cannot be clinically classified as Polycythemia vera [6]. This evidence concerns the gene BCR and myeloproliferative neoplasm.